Resources

David Cooper, UK Project Pursuit at new BIA member Emerson, answers questions about the company.

Dr Danuta Jeziorska outlines that the UK has a unique opportunity to lead in genomics and AI-driven precision medicine, but a critical early-stage funding gap—particularly for drug target discovery companies—threatens its global competitiveness.

PrecisionLife has been awarded a €2.5m non-dilutive grant by the European Innovation Council (EIC) for its TRANSCEND project, to more rapidly and accurately triage and treat patients with endometriosis.

Stablepharma Ltd has secured a €2.5 million EIC Accelerator grant, recognizing its pioneering fridge-free pharmaceutical technology.

Axplora unveils a €50 million investment at its Mourenx site, strengthening its role in producing next-generation therapies, including GLP-1 drugs for diabetes and obesity.

Isomorphic Labs has expanded its strategic collaboration with Novartis, adding up to three new research programs to accelerate AI-driven drug discovery. This deepened partnership underscores the transformative potential of AI in tackling some of the most challenging targets in medicine.

GitLife Biotech and Colorifix have partnered to enhance traceability and scalability in eco-friendly textile dyeing. The project is supported by Innovate UK.

Co-designing new networks with research users is critical to delivering the full scientific and commercial value of NHS health data.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

The relaunched APPG for Life Sciences holds its inaugural parliamentary reception, bringing together MPs, Peers, and sector leaders to showcase UK life sciences innovation.

 This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.

Unlike conventional approaches, AbDrop™ directly screens naturally matured individual B cells, maximizing CDR diversity by mining the entire plasma cell repertoire. This high-throughput system enables rapid identification of natively paired sequences, significantly reducing the discovery timeline to just 2–3 months.

Intelligent upgrade of existing, purpose-built laboratory spaces will be available for occupation from Q3, 2025.

Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme hosted by leading science and innovation campus Discovery Park, in Sandwich, Kent.

Melio Bio, a biotech dedicated to the discovery and development of novel inhibitors targeting a receptor implicated in obesity and associated co-morbidities, has been revealed as the winner of Pioneer Group and Novo Nordisk’s 2025 Golden Ticket Programme.

In this article, Giuseppe Amoroso, R&D Tax Advisor for biotech companies, explores the critical role of R&D tax compliance in the biotechnology sector.

Coulter Partners successfully completed a search assignment for Bausch Health Companies and is pleased to announce the placement of Jonathan Sadeh M.D., M.Sc., as Executive Vice President, Chief Medical Officer and Head of R&D.

Glox Therapeutics' expanded team to support development and commercialisation of precision antibiotics to help overcome antimicrobial resistance.

A new network will foster collaboration among regulators, industry, and researchers to ensure there is a world-leading regulatory environment in the UK for advanced therapies that supports companies in the development, trial, and launch of these innovative treatments.